The impact of comorbidities on costs, utilities and health-related quality of life among HIV patients in a clinical setting in Bogotá.

Mark Jm Van DuinRafael CondeBen WijnenSilvia M A A EversJavier L Gonzalez-RodriguezMark Jg GoversMickaël J C Hiligsmann

Published in: Expert review of pharmacoeconomics & outcomes research (2016)

This study suggests that having multiple CMs significantly influences utility, and CMs have some impact on HRQOL measured using the EQ-VAS but this effect is at the border of significance. No significant impact was observed on costs.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
antiretroviral therapy
hiv infected
hepatitis c virus
human immunodeficiency virus
hiv positive
peritoneal dialysis
prognostic factors
hiv testing
hiv aids
men who have sex with men
patient reported outcomes